NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$131.23
+2.43% today
Updated 2026-04-29
Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
—
52W range
$108 – $160
Volume
1.1M
Neurocrine Biosciences Inc (NBIX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
16.70%
Operating margin
28.20%
ROE
16.40%
ROA
9.53%
Debt/equity
0.13x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $39.23M | $-107.20M | 100.00% | -288.82% | -273.25% |
| 2007 | $1.22M | $-207.30M | 100.00% | -17,340.03% | -16,936.19% |
| 2008 | $3.98M | $-88.61M | 100.00% | -2,196.18% | -2,229.26% |
| 2009 | $2.95M | $-51.04M | 100.00% | -1,817.47% | -1,728.34% |
| 2010 | $33.50M | $-7.97M | 100.00% | -40.96% | -23.78% |
| 2011 | $77.41M | $37.57M | 100.00% | 43.82% | 48.53% |
| 2012 | $53.14M | $5.03M | 78.17% | 2.72% | 9.46% |
| 2013 | $2.92M | $-46.09M | -372.76% | -1,701.88% | -1,578.97% |
| 2014 | $0.00 | $-60.54M | — | — | — |
| 2015 | $19.77M | $-88.93M | 100.00% | -476.51% | -449.84% |
| 2016 | $15.00M | $-141.09M | 100.00% | -982.48% | -940.60% |
| 2017 | $161.63M | $-142.54M | 99.22% | -81.27% | -88.19% |
| 2018 | $451.24M | $21.11M | 98.92% | 8.18% | 4.68% |
| 2019 | $788.10M | $37.00M | 99.06% | 9.17% | 4.69% |
| 2020 | $1.05B | $407.30M | 99.03% | 15.58% | 38.94% |
| 2021 | $1.13B | $89.60M | 98.74% | 9.04% | 7.90% |
| 2022 | $1.49B | $154.50M | 98.44% | 16.73% | 10.38% |
| 2023 | $1.89B | $249.70M | 97.90% | 13.30% | 13.23% |
| 2024 | $2.36B | $341.30M | 98.56% | 24.22% | 14.49% |
| 2025 | $2.86B | $478.60M | 98.18% | 21.64% | 16.73% |